干扰素联合珍珠草乙肝舒康胶囊治疗慢性乙型肝炎临床研究

Clinical Study of Interferon-α Combining with Zhenzhucao Yiganshukang Capsule on Treating Chronic Hepatitis B

目的探讨干扰素(IFN)α-2b联合珍珠草乙肝舒康胶囊治疗病毒性慢性乙型肝炎(CHB)抗病毒作用的临床疗效。方法94例CHB患者随机分为3组,分别接受单纯护肝药物(对照组)、IFNα-2b(干扰素治疗组)及IFNα-2b联合珍珠草乙肝舒康胶囊(联合用药组)治疗,疗程24周。观察血清HBV-DNA及HBsAg、HBeAg的阴转情况。结果IFNα-2b组及联合治疗组的抗病毒疗效均优于对照组(P<0.05),且联合用药组的HBV-DNA的复制水平下降率及HBsAg阴转率均高于干扰素组。结论干扰素与珍珠草乙肝舒康胶囊有协同抗病毒作用,且疗效优于单用干扰素治疗。

Objective To evaluate the therapeutic efficacy of alpha interferon combining with Zhenzhucao Yiganshukang capsule on patients with chronic hepatitis B. Methods 94 chronic hepatitis B patients with HBV-DNA, HBsAg and HBeAg positive were randomly subdivided into three groups: The control group was given by usual medicine for six months. The alpha interferon group was treated by INFα-2b for six months. The group of alpha interferon combining with Zhenzhucao Yiganshukang capsule was treated by INF-α and Zhenzucao Yiganshukang capsule for six months. And investigated the changes of liver function, HBV-DNA and the negative ratio of HbsAg, HBeAg after treatment. Result Efficacy of HBV-DNA and the negative ratio of HbsAg, HBeAg of both the INF-α group and the combine group was higher than the control group. Efficacy of HBV-DNA and the negative ratio of HBsAg of the combine group were higher than both the INF-α group and the control group. There were no significant difference between the combine group and the INF-α group on the negative ratio of HBeAg. Conclusion The combine of alpha interferon and Zhenzhucao Yiganshukang capsule can improve antivirus effect of chronic hepatitis B.